Cytovia Overview
- Status
- Acquired/Merged
- Latest Deal Type
- PIPE
- (Announced)
- Financing Rounds
- 5
- Investments
- 3
Cytovia General Information
Description
Operator of a biopharmaceutical company intended to address several of the unmet medical needs in oncology. The company's bio-medicines and drugs include a patented drug screening technology that discovers and develops small-molecule inhibitors and activators of capsules, enabling the patients to fight cancer through stem cell engineering and multispecific antibodies.
Contact Information
Website
www.cytoviatx.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Parent Company
Primary Office
- 18851 North East 29th Avenue
- 2nd Floor
- Aventura, FL 33180
- United States
+1 (786) 000-0000
Cytovia Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Cytovia‘s full profile, request access.
Request a free trialCytovia Patents
Cytovia Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-7732468-B2 | 3-(3-ethyl-1-methyl-1h-pyrazol-5-yl)-6-p-tolyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole; to treat ameliorating neoplasia; cancers; infectious viral disease, autoimmune disease; rheumatoid arthritis; inflammatory diseases; skin diseases like psoriasis | Expired - Fee Related | 15-Nov-2006 | 00000000000 | |
| US-20080113984-A1 | 3-(3-ethyl-1-methyl-1h-pyrazol-5-yl)-6-p-tolyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole; to treat ameliorating neoplasia; cancers; infectious viral disease, autoimmune disease; rheumatoid arthritis; inflammatory diseases; skin diseases like psoriasis | Granted | 15-Nov-2006 | 00000000000 | 0 |
| CA-2657931-A1 | 3-aryl-6-aryl-7h-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof | Abandoned | 18-Jul-2006 | 000000000 | |
| US-20080045514-A1 | 3-aryl-6-aryl-7h-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof | Abandoned | 18-Jul-2006 | 000000000 | 0 |
| EP-2046336-A4 | 3-aryl-6-aryl-7h-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof | Withdrawn | 18-Jul-2006 | A61K31/53 | 0 |
Cytovia Executive Team (15)
Cytovia Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000000 0000000 | Cytovia | Co-Founder, Acting Chief Business Officer, Corporate Secretary and Board Member | 000 0000 |
| 00000 00000 | Self | Board Member | 000 0000 |
| 0000000 000000 00.0 | Self | Board Member & Co-Founder | 000 0000 |
| 0000000 00000000 00.0 | Self | Co-Founder & Board Member | 000 0000 |
| 0000000 00000000 00 | Self | Co-Founder and Board Member | 000 0000 |
Cytovia Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore Cytovia‘s full profile, request access.
Request a free trialCytovia Investments & Acquisitions (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000 000 | 26-Apr-2022 | 0000000000 | Special Purpose Acquisition Company (SPAC) | 000000 00 | |
| 00000000 0000 | 13-Sep-2021 | 00000 0000 | 0000 | Biotechnology | 000000 00 |
| CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) | 03-Aug-2020 | Corporate Asset Purchase | Buildings and Property | 000000 00 |